根据美国证券交易委员会最新备案文件披露,Apimeds Pharmaceuticals US Inc(股票代码:APUS)已正式任命蔡成俊(Sungjoon Chae)担任公司联席首席执行官。此项高管人事变动将于2026年5月4日正式生效。
此次任命标志着该公司在战略领导层配置上的重要调整。蔡成俊将与其他高管团队协同工作,共同推动公司的业务发展和战略规划实施。
根据美国证券交易委员会最新备案文件披露,Apimeds Pharmaceuticals US Inc(股票代码:APUS)已正式任命蔡成俊(Sungjoon Chae)担任公司联席首席执行官。此项高管人事变动将于2026年5月4日正式生效。
此次任命标志着该公司在战略领导层配置上的重要调整。蔡成俊将与其他高管团队协同工作,共同推动公司的业务发展和战略规划实施。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.